Peptide Therapeutics
•41 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (41)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Peptide therapeutics (tirzepatide family) are a core part of Lilly's portfolio.
|
$972.49B |
$1053.75
+2.55%
|
|
ABBV
AbbVie Inc.
Nimble Therapeutics’ IL23R inhibitor and peptide platform contribute to AbbVie’s peptide therapeutics pipeline.
|
$394.51B |
$226.96
+1.63%
|
|
AZN
AstraZeneca PLC
Peptide therapeutics (e.g., oral GLP-1) represent a peptide-based modality in AZN's pipeline.
|
$278.47B |
$91.06
+1.37%
|
|
NVO
Novo Nordisk A/S
Semaglutide-based peptide therapeutics comprise the company’s differentiated platform (GLP-1 peptides) and core pipeline.
|
$226.31B |
$50.38
+0.41%
|
|
RDY
Dr. Reddy's Laboratories Limited
Peptide therapeutics focus within GLP-1 programs and related peptide APIs/formulations.
|
$11.69B |
$14.04
+0.18%
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$8.41B |
$36.06
-3.09%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide) is a peptide-based therapeutic, fitting the peptide therapeutics category.
|
$7.54B |
$113.12
-0.39%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.93B |
$94.31
-1.09%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
DAYBUE (trofinetide) and ACP-101 intranasal carbetocin are peptide therapeutics, supporting a peptide therapeutics business.
|
$4.58B |
$26.92
-0.85%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$4.17B |
$36.15
-2.52%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
GLP-1 collaboration and peptide drug substance/finish capabilities map to Peptide Therapeutics.
|
$3.83B |
$12.36
+1.23%
|
|
ETNB
89bio, Inc.
Pegozafermin is a peptide-based therapeutic; directly marketed as a Peptide Therapeutics product.
|
$2.17B |
$14.85
+0.07%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
Avexitide is a peptide-based GLP-1 receptor antagonist, aligning with the 'Peptide Therapeutics' tag.
|
$1.17B |
$12.76
-2.63%
|
|
OPK
OPKO Health, Inc.
OPK-88006 is a dual GLP-1/glucagon peptide therapeutic (peptide therapeutics).
|
$1.10B |
$1.37
-0.72%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX's lead programs are peptide-based therapeutics delivered via a proprietary long-acting Precision Endocrine Peptide (PEP™) platform, i.e., Peptide Therapeutics.
|
$1.00B |
$28.13
-5.79%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$581.51M |
$3.69
+2.93%
|
|
BCYC
Bicycle Therapeutics plc
Bicycle molecules are fully synthetic peptide therapeutics used to target cancer.
|
$516.33M |
$7.21
-3.22%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$485.36M |
$8.71
-7.24%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$465.12M |
$5.33
+1.23%
|
|
ETON
Eton Pharmaceuticals, Inc.
ETON's portfolio includes peptide-based medicines (e.g., desmopressin in ET-600), which fits the Peptide Therapeutics investable theme.
|
$447.85M |
$16.04
-3.95%
|
|
CATX
Perspective Therapeutics, Inc.
Pipeline includes peptide-based targeting constructs used to deliver radiopharmaceuticals.
|
$198.28M |
$2.60
-2.62%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
ELTX
Elicio Therapeutics, Inc.
Peptide components referenced in AMP program, aligning with Peptide Therapeutics.
|
$133.73M |
$8.58
+4.83%
|
|
VTGN
VistaGen Therapeutics, Inc.
PH94B and related pherine candidates are peptide-based, aligning with peptide therapeutics.
|
$130.39M |
$4.38
+3.06%
|
|
ENTX
Entera Bio Ltd.
Entera Bio develops peptide therapeutics (EB613, EB612, OPK-88006) and related oral peptide programs.
|
$98.63M |
$2.16
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-114 is a GLP-1/GLP-2 dual-agonist peptide program, placing the company in the peptide therapeutics space.
|
$96.30M |
$1.43
+6.72%
|
|
VANI
Vivani Medical, Inc.
Lead programs NPM-115 and NPM-139 are peptide-based GLP-1 receptor agonists, aligning with Peptide Therapeutics.
|
$79.98M |
$1.38
+2.22%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$74.81M |
$8.08
+2.02%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Peptide therapeutics (AI-designed GLP-1 peptides) being developed as internal assets.
|
$58.15M |
N/A
|
|
CUE
Cue Biopharma, Inc.
The platform's peptide-MHC components align with Peptide Therapeutics as a major product modality.
|
$37.43M |
$0.48
-1.48%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 is described as a peptide therapeutic, placing the company in the Peptide Therapeutics category.
|
$36.12M |
$1.43
-8.06%
|
|
PYPD
PolyPid Ltd.
GLP-1 program uses the PLEX platform to deliver long-acting peptide therapeutics (GLP-1) for metabolic diseases.
|
$18.81M |
$3.98
+1.66%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$17.51M |
$2.04
+2.00%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-VA's GDNF-based therapy could be categorized as peptide therapeutics (protein/peptide modality).
|
$15.51M |
$1.12
-3.85%
|
|
BIVI
BioVie Inc.
BIV201 is a continuous-infusion peptide therapy (terlipressin) for liver cirrhosis, mapping to 'Peptide Therapeutics'.
|
$10.92M |
$1.37
-5.52%
|
|
BLRX
BioLineRx Ltd.
Motixafortide is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$7.94M |
$3.24
-2.11%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Lead asset hCDR1 is a peptide-based therapeutic, fitting the Peptide Therapeutics category.
|
$4.63M |
$0.83
-2.27%
|
|
BZYR
Burzynski Research Institute, Inc.
Antineoplastons are peptide-based therapeutics; core product category is peptide therapeutics.
|
$4.22M |
$0.03
|
|
SILO
Silo Pharma, Inc.
Peptide Therapeutics applies to SPU-16 CNS-homing peptide and related peptide-based delivery/therapeutics platforms.
|
$4.08M |
$0.43
-1.20%
|
|
AAGH
America Great Health
Focus on peptide/protein therapeutics as a core research and therapeutic development area.
|
$2.12M |
$0.00
|
Loading company comparison...
Loading industry trends...
Loading research report...
